• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Bunn, Paul A
    Thatcher, Nick
    Affiliation
    University of Colorado Cancer Center, Aurora, Colorado, USA.
    Issue Date
    2008
    
    Metadata
    Show full item record
    Abstract
    Lung cancer is the most common cancer and a highly lethal disease, with improvements in survival rates being dependent on advances in early detection and improved systemic therapies applied to surgery and/or irradiation in early-stage disease. Non-small cell lung cancer (NSCLC) represents around 80% of all lung cancers, and unfortunately at diagnosis most patients have advanced unresectable disease with a very poor prognosis. Indeed, 30%-40% of patients treated with first-line therapy will subsequently be candidates for second-line treatment. Current U.S. Food and Drug Administration-approved second-line treatments are docetaxel (a taxane), pemetrexed (a folate antimetabolite), and erlotinib (an epidermal growth factor receptor [EGFR] tyrosine kinase inhibitor [TKI]). Gefitinib, another EGFR TKI, currently has only limited use in North America and is not available in Europe. These and other new molecular-target-specific agents may have the potential to maximize therapeutic benefit while minimizing toxicity to normal cells. Overexpression of EGFR is reported to occur in 40%-80% of NSCLC cases, and EGFR mutations are associated with a significantly higher response rate and longer duration of response following treatment with EGFR TKIs. Another option is antiangiogenesis: the growth and persistence of solid tumors and their metastases are angiogenesis dependent, and so antiangiogenic therapies have been developed, such as the use of TKIs that block the vascular endothelial growth factor receptor. In fact, many commonly used chemotherapeutic drugs have antiangiogenic activity. Ongoing studies are focusing on patient selection and targeted therapies, and there are many new agents undergoing clinical trials.
    Citation
    Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction. 2008, 13 Suppl 1:1-4 Oncologist
    Journal
    The Oncologist
    URI
    http://hdl.handle.net/10541/59113
    DOI
    10.1634/theoncologist.13-S1-1
    PubMed ID
    18263768
    Type
    Article
    Language
    en
    ISSN
    1083-7159
    ae974a485f413a2113503eed53cd6c53
    10.1634/theoncologist.13-S1-1
    Scopus Count
    Collections
    All Christie Publications
    Medical Oncology

    entitlement

    Related articles

    • Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion.
    • Authors: Bunn PA Jr, Thatcher N
    • Issue date: 2008
    • Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.
    • Authors: Patel JD, Pasche B, Argiris A
    • Issue date: 2004 Jun
    • Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
    • Authors: John T, Liu G, Tsao MS
    • Issue date: 2009 Aug
    • Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
    • Authors: Bonomi PD, Buckingham L, Coon J
    • Issue date: 2007 Aug 1
    • [Second-line treatment and targeted therapy of advanced lung cancer].
    • Authors: Nakamura Y, Yamamoto N
    • Issue date: 2009 May
    DSpace software (copyright © 2002 - 2019)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.